company background image
ALCAR logo

Carmat ENXTPA:ALCAR Stock Report

Last Price

€4.03

Market Cap

€99.9m

7D

5.5%

1Y

-55.0%

Updated

27 Mar, 2024

Data

Company Financials +

ALCAR Stock Overview

Carmat SA designs and develops total artificial heart for people suffering from end-stage biventricular heart failure in France and internationally.

ALCAR fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Carmat SA Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Carmat
Historical stock prices
Current Share Price€4.03
52 Week High€9.99
52 Week Low€3.00
Beta1.3
1 Month Change-3.47%
3 Month Change-36.44%
1 Year Change-55.02%
3 Year Change-84.53%
5 Year Change-82.63%
Change since IPO-81.76%

Recent News & Updates

Recent updates

Health Check: How Prudently Does Carmat (EPA:ALCAR) Use Debt?

Dec 15
Health Check: How Prudently Does Carmat (EPA:ALCAR) Use Debt?

Increases to Carmat SA's (EPA:ALCAR) CEO Compensation Might Cool off for now

May 05
Increases to Carmat SA's (EPA:ALCAR) CEO Compensation Might Cool off for now

Carmat (EPA:ALCAR) Is Carrying A Fair Bit Of Debt

Mar 02
Carmat (EPA:ALCAR) Is Carrying A Fair Bit Of Debt

Shareholder Returns

ALCARFR Medical EquipmentFR Market
7D5.5%0.6%0.4%
1Y-55.0%27.4%9.6%

Return vs Industry: ALCAR underperformed the French Medical Equipment industry which returned 27.7% over the past year.

Return vs Market: ALCAR underperformed the French Market which returned 10.6% over the past year.

Price Volatility

Is ALCAR's price volatile compared to industry and market?
ALCAR volatility
ALCAR Average Weekly Movement9.4%
Medical Equipment Industry Average Movement5.3%
Market Average Movement4.2%
10% most volatile stocks in FR Market9.8%
10% least volatile stocks in FR Market2.2%

Stable Share Price: ALCAR's share price has been volatile over the past 3 months.

Volatility Over Time: ALCAR's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of French stocks.

About the Company

FoundedEmployeesCEOWebsite
2008177Stephane Piathttps://www.carmatsa.com

Carmat SA designs and develops total artificial heart for people suffering from end-stage biventricular heart failure in France and internationally. Its product includes Aeson, an active implantable medical device intended to replace the ventricles of the native heart in patients suffering from advanced heart failure. The company was incorporated in 2008 and is headquartered in Vélizy-Villacoublay, France.

Carmat SA Fundamentals Summary

How do Carmat's earnings and revenue compare to its market cap?
ALCAR fundamental statistics
Market cap€99.87m
Earnings (TTM)-€54.36m
Revenue (TTM)€910.00k

109.7x

P/S Ratio

-1.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALCAR income statement (TTM)
Revenue€910.00k
Cost of Revenue€43.82m
Gross Profit-€42.91m
Other Expenses€11.45m
Earnings-€54.36m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

Apr 24, 2024

Earnings per share (EPS)-2.19
Gross Margin-4,715.38%
Net Profit Margin-5,974.07%
Debt/Equity Ratio-649.2%

How did ALCAR perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.